Decreased mitochondrial SIRT3 expression is a potential molecular biomarker associated with poor outcome in breast cancer

Human Pathology

Volumn 45, Issue 5, 2014, Pages 1071-1077

  Desouki, Mohamed Mokhtar ^a   Doubinskaia, Irina ^a   Gius, David ^b   Abdulkadir, Sarki A ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Breast cancer; Clinical outcomes; Metabolism; Mitochondria; Sirt3; Sirtuins

Indexed keywords

BREAST CANCER; CLINICAL OUTCOMES; METABOLISM; MITOCHONDRIA; SIRT3; SIRTUINS;

BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; MITOCHONDRIA; PROGNOSIS; SIRTUIN 3; TUMOR MARKERS, BIOLOGICAL;

EID: 84898783930     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2014.01.004     Document Type: Article

References (30)

1. W.B. Ershler, and D.L. Longo The biology of aging: the current research agenda Cancer 80 1997 1284 1293
2. V.D. Longo, and B.K. Kennedy Sirtuins in aging and age-related disease Cell 126 2006 257 268
3. E.J. Kim, J.H. Kho, M.R. Kang, and S.J. Um Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity Mol Cell 28 2007 277 290
4. M. Kaeberlein, M. McVey, and L. Guarente The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms Genes Dev 13 1999 2570 2580
5. S. Imai, C.M. Armstrong, M. Kaeberlein, and L. Guarente Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase Nature 403 2000 795 800
6. H.S. Kim, K. Patel, and K. Muldoon-Jacobs et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress Cancer Cell 17 2010 41 52
7. H.S. Kim, A. Vassilopoulos, and R.H. Wang et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity Cancer Cell 20 2011 487 499
8. L. Guarente Sir2 links chromatin silencing, metabolism, and aging Genes Dev 14 2000 1021 1026
9. R.A. Frye Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins Biochem Biophys Res Commun 273 2000 793 798
10. W.C. Hallows, B.N. Albaugh, and J.M. Denu Where in the cell is SIRT3? Functional localization of an NAD+-dependent protein deacetylase Biochem J 411 2008 e11 e13
11. T. Finkel, C.X. Deng, and R. Mostoslavsky Recent progress in the biology and physiology of sirtuins Nature 460 2009 587 591
12. L. Guarente, L. Partridge, and D.C. Wallace Molecular biology of aging 2008 Cold Spring Harbor Laboratory Press Cold Spring Harbor, NY
13. N.R. Sundaresan, M. Gupta, G. Kim, S.B. Rajamohan, A. Isbatan, and M.P. Gupta Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice J Clin Invest 119 2009 2758 2771
14. D. Harman Aging: a theory based on free radical and radiation chemistry J Gerontol 11 1956 298 300
15. D.R. Spitz, E.I. Azzam, J.J. Li, and D. Gius Metabolic oxidation/reduction reactions and cellular responses to ionizing radiation: a unifying concept in stress response biology Cancer Metastasis Rev 23 2004 311 322
16. M. Valko, D. Leibfritz, J. Moncol, M.T. Cronin, M. Mazur, and J. Telser Free radicals and antioxidants in normal physiological functions and human disease Int J Biochem Cell Biol 39 2007 44 84
17. R. Tao, M.C. Coleman, and J.D. Pennington et al. Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress Mol Cell 40 2010 893 904
18. M.D. Hirschey, T. Shimazu, and E. Goetzman et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation Nature 464 2010 121 125
19. I.R. Lanza, D.K. Short, and K.R. Short et al. Endurance exercise as a countermeasure for aging Diabetes 57 2008 2933 2942
20. L.W. Finley, A. Carracedo, and J. Lee et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization Cancer Cell 19 2011 416 428
21. S.A. Abdulkadir, G.F. Carvalhal, Z. Kaleem, W. Kisiel, P.A. Humphrey, W.J. Catalona, and J. Milbrandt Tissue factor expression and angiogenesis in human prostate carcinoma Hum Pathol 31 2000 443 447
22. M. Nadji, C. Gomez-Fernandez, P. Ganjei-Azar, and A.R. Morales Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers Am J Clin Pathol 123 2005 21 27
23. M.E. Hammond, D.F. Hayes, and M. Dowsett et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer Arch Pathol Lab Med 134 2010 907 922
24. B. Gyorffy, and R. Schafer Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients Breast Cancer Res Treat 118 2009 433 441
25. W.A. Cunningham, K.J. Preacher, and M.R. Banaji Implicit attitude measures: consistency, stability, and convergent validity Psychol Sci 12 2001 163 170
26. J.D. Brenton, L.A. Carey, A.A. Ahmed, and C. Caldas Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23 2005 7350 7360
27. S.H. Park, O. Ozden, and H. Jiang et al. Sirt3, mitochondrial ROS, ageing, and carcinogenesis Int J Mol Sci 12 2011 6226 6239
28. K. Xiao, J. Jiang, and W. Wang et al. Sirt3 is a tumor suppressor in lung adenocarcinoma cells Oncol Rep 30 2013 1323 1328
29. Y. Zhang, Y. Sun, and Y. Pan et al. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis Clin Cancer Res 18 2012 1947 1953
30. M. Razandi, A. Pedram, V.C. Jordan, S. Fuqua, and E.R. Levin Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer Oncogene 32 2013 3274 3285